期刊文献+

肾透明细胞癌患者血清中miR-21的表达及其临床意义

The changes of expression levels of miR-21 in the serum of patients with renal cell carcinoma
下载PDF
导出
摘要 目的探讨肾癌患者与健康人血清中miR-21的表达差异及其切除肿瘤组织后血清中的表达变化,为后期深入性研究奠定理论基础。方法收集新疆医科大学第一附属医院泌尿外科新诊断肾癌患者30例术前血清样本(cRCC组),并于术后1个月收集其血清,另选择30例健康志愿者血清作为对照组,采用实时荧光定量PCR技术检测cRCC组术前、术后和对照组血清中miR-21的表达。结果 cRCC组术前、术后及对照组血清中miR-21的表达水平差异有统计学意义(Kruskal-wallis H秩和检验,H≈χ2,P=0.001),cRCC组术前血清中miR-21表达水平是对照组的12.99倍(Z=-3.252,P=0.001),术后的表达水平是对照组的1.03倍(Z=-0.103,P=0.918),cRCC组术后血清中miR-21表达水平较术前明显下降(Z=-3.349,P=0.001)。结论肾癌患者血清中miR-21明显高表达,在切除肿瘤组织后其表达水平明显下降,提示其与肾肿瘤密切相关,是肾癌潜在分子标记物。 Objective To investigate the expression levels of miR-21 in the serum of patients with renal cell carcinoma,and to lay a theoretical foundation for the in-depth study in the future.Methods 30 serum samples of patients with renal cell carcinoma was collected before surgery,and the blood serum samples were collected again after surgery a month later.Moreover,the study includes 30 healthy controls.The expression levels of miR-21 in the serum of samples from three groups were compared by using the real-time PCR.Results miR-21 expression in serum have statistical significance amang renal clear cell carcinoma,post-operation and normal group(Kruskal-wallis H rank sum test H,H≈χ^2= 14.882,P = 0.001).compared with the normal group,miR-21 expression in renal cell carcinoma is 12.99 times(Z =-3.252,P = 0.001),and in post-operation is 1.03 times(Z =-0.103 P= 0.918).Conclusion The expression levels of miR-21 in the serum in patients with renal cell carcinoma is significantly increased,while it decreased significantly after resection.The outcome suggests that the expression levels of miR-21 in the serum is closely related with renal cell carcinoma.Therefore,miR-21 can be regarded as a potential molecular marker in renal cell carcinoma.
出处 《新疆医科大学学报》 CAS 2015年第5期539-542,共4页 Journal of Xinjiang Medical University
基金 国家自然科学基金(81060210) 新疆维吾尔自治区自然科学基金重大项目(2013211A101) 新疆医科大学校级科研项目(2012YFY28)
关键词 血清microRNAs 肾癌 MIR-21 分子标记物 serum microRNAs renal cell carcinoma miR-21 molecular markers
  • 相关文献

参考文献2

二级参考文献34

  • 1Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262.
  • 2Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future, lnt J Biol Markers 2001; 16:73-86.
  • 3Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J lntern Med 2007; 18:175-184.
  • 4Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990; 77:961-962.
  • 5Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
  • 7Chen C, Ridzon DA, Broomer A J, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
  • 8Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
  • 9Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3-12.
  • 10Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-2261.

共引文献984

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部